199 related articles for article (PubMed ID: 32923156)
41. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response.
Pockaj BA; Sherry RM; Wei JP; Yannelli JR; Carter CS; Leitman SF; Carasquillo JA; Steinberg SM; Rosenberg SA; Yang JC
Cancer; 1994 Mar; 73(6):1731-7. PubMed ID: 8156501
[TBL] [Abstract][Full Text] [Related]
42. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix.
Santin AD; Bellone S; Palmieri M; Bossini B; Roman JJ; Cannon MJ; Bignotti E; Canè S; Pecorelli S
Gynecol Oncol; 2003 May; 89(2):271-80. PubMed ID: 12713991
[TBL] [Abstract][Full Text] [Related]
43. Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.
Zikich D; Schachter J; Besser MJ
Immunotherapy; 2016; 8(1):35-43. PubMed ID: 26653685
[TBL] [Abstract][Full Text] [Related]
44. Focus on adoptive T cell transfer trials in melanoma.
Hershkovitz L; Schachter J; Treves AJ; Besser MJ
Clin Dev Immunol; 2010; 2010():260267. PubMed ID: 21234353
[TBL] [Abstract][Full Text] [Related]
45. Tissue Harvesting for Adoptive Tumor Infiltrating Lymphocyte Therapy in Metastatic Melanoma.
Zippel D; Friedman-Eldar O; Rayman S; Hazzan D; Nissan A; Schtrechman G; Markel G; Schachter J; Itzhaki O; Besser MJ
Anticancer Res; 2019 Sep; 39(9):4995-5001. PubMed ID: 31519606
[TBL] [Abstract][Full Text] [Related]
46. Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer.
Santin AD; Bellone S; Palmieri M; Bossini B; Cane' S; Bignotti E; Roman JJ; Cannon MJ; Pecorelli S
Int J Gynecol Cancer; 2004; 14(1):64-75. PubMed ID: 14764031
[TBL] [Abstract][Full Text] [Related]
47. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
[TBL] [Abstract][Full Text] [Related]
48. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
49. Successful treatment of melanoma brain metastases with adoptive cell therapy.
Hong JJ; Rosenberg SA; Dudley ME; Yang JC; White DE; Butman JA; Sherry RM
Clin Cancer Res; 2010 Oct; 16(19):4892-8. PubMed ID: 20719934
[TBL] [Abstract][Full Text] [Related]
50. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.
Powell DJ; Dudley ME; Hogan KA; Wunderlich JR; Rosenberg SA
J Immunol; 2006 Nov; 177(9):6527-39. PubMed ID: 17056585
[TBL] [Abstract][Full Text] [Related]
51. Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy.
van de Donk PP; Wind TT; Hooiveld-Noeken JS; van der Veen EL; Glaudemans AWJM; Diepstra A; Jalving M; de Vries EGE; de Vries EFJ; Hospers GAP
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4369-4376. PubMed ID: 34076745
[TBL] [Abstract][Full Text] [Related]
52. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.
Kandalaft LE; Powell DJ; Chiang CL; Tanyi J; Kim S; Bosch M; Montone K; Mick R; Levine BL; Torigian DA; June CH; Coukos G
Oncoimmunology; 2013 Jan; 2(1):e22664. PubMed ID: 23482679
[TBL] [Abstract][Full Text] [Related]
53. Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells.
Kass R; Bellone S; Palmieri M; Canè S; Bignotti E; Henry-Tillman R; Hutchins L; Cannon MJ; Klimberg S; Santin AD
Breast Cancer Res Treat; 2003 Aug; 80(3):275-85. PubMed ID: 14503800
[TBL] [Abstract][Full Text] [Related]
54. Prospects for gene therapy and lymphokine therapy for metastatic melanoma.
Sivanandham M; Scoggin SD; Sperry RG; Wallack MK
Ann Plast Surg; 1992 Jan; 28(1):114-8. PubMed ID: 1642399
[TBL] [Abstract][Full Text] [Related]
55. Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy.
Itzhaki O; Hovav E; Ziporen Y; Levy D; Kubi A; Zikich D; Hershkovitz L; Treves AJ; Shalmon B; Zippel D; Markel G; Shapira-Frommer R; Schachter J; Besser MJ
J Immunother; 2011 Mar; 34(2):212-20. PubMed ID: 21304398
[TBL] [Abstract][Full Text] [Related]
56. Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases.
Mehta GU; Malekzadeh P; Shelton T; White DE; Butman JA; Yang JC; Kammula US; Goff SL; Rosenberg SA; Sherry RM
J Immunother; 2018 Jun; 41(5):241-247. PubMed ID: 29672342
[TBL] [Abstract][Full Text] [Related]
57. Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy.
Nissani A; Lev-Ari S; Meirson T; Jacoby E; Asher N; Ben-Betzalel G; Itzhaki O; Shapira-Frommer R; Schachter J; Markel G; Besser MJ
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33990415
[TBL] [Abstract][Full Text] [Related]
58. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
[TBL] [Abstract][Full Text] [Related]
59. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option.
Rohaan MW; van den Berg JH; Kvistborg P; Haanen JBAG
J Immunother Cancer; 2018 Oct; 6(1):102. PubMed ID: 30285902
[TBL] [Abstract][Full Text] [Related]
60. Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness.
Lindenberg M; Retèl V; Rohaan M; van den Berg J; Haanen J; van Harten W
BMC Cancer; 2020 Jul; 20(1):712. PubMed ID: 32736535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
